UBS reiterates Buy on MBX Biosciences stock ahead of Q4 obesity data
Covered in this story
What has happened since
- Mbx Biosciences Inc is down 12.3% since this was published, 24 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
UBS’s $90 target on $MBX is on the record and being tracked to Sep 2027 (12-month default), scored on the close that day.
UBS’s track record →Call it yourself
No member calls on $MBX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Mbx Biosciences Inc →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.